尊龙凯时人生就是搏

The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of Category 1 Drug ZSP0678 for a new indication, Primary Biliary Cholangitis (PBC).

Today, the gathering of CHBD was held in Shenzhen with more than 150 members in Greater Bay Area attending at the Kexing Science Park.

Today, Guangdong Biopharmaceutical Innovation Technology Association Membership Conference 2019 and Innovation Forum for Pharmaceutical Enterprises under the New Situation was successfully held at the International Conference Center of Guangzhou Sunshine Hotel.

Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd has signed a strategic cooperation agreement with Guangdong Raffles Pharmaceutical Technology Co., Ltd and announced further in-depth cooperation in API process optimization, clinical sample preparation and new drugs commercial production.

From September 11 to 12, 2019, Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019 was successfully held at Shenzhen Yanzi Lake International Convention and Exhibition Center.